What is the latest on a new drug called selinexor?

In this week’s video, Dr. Brian G.M. Durie details the results of the STORM 2b trial, which uses selinexor in combination with dexamethasone to treat multiple myeloma patients who are refractory to IMiDs, proteasome inhibitors, and daratumumab.

BOTTOM LINE:
Selinexor will likely be approved by the FDA, demonstrating its safety and efficacy in combination with other myeloma therapies.

If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected]

To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected]

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

 

Video
IMF TV Blog Category
Old Id
1533

Source URL: https://www.myeloma.org/videos/latest-new-drug-called-selinexor